Literature DB >> 18690355

L-Asparaginase and the effect of age on coagulation and fibrinolysis in childhood acute lymphoblastic leukemia.

Inge M Appel1, Wim C J Hop, Carla van Kessel-Bakvis, Rolinda Stigter, Rob Pieters.   

Abstract

Alterations in haemostasis are frequently observed in children with acute lymphoblastic leukemia (ALL). It was the objective of this study to analyse age-related disturbances in coagulation and fibrinolysis parameters during the induction phase of the antileukemic treatment. Sixty-four children were classified by age into three groups (1-5, 6-10, 11-16 years), and studied during induction treatment of ALL including four weeks of dexamethasone, followed by two weeks tapering of dexamethasone during which 6,000 IU/m(2) native L-Asparaginase (total 4 doses) was administered intravenously twice weekly. Blood samples were collected immediately before each L-Asparaginase infusion to analyze procoagulant (fibrinogen, factor [F] II, FV, FVII, F IX, F X) and anticoagulant factors (antithrombin [AT], protein C, protein S), parameters of thrombin generation (F1+2, TAT) and fibrinolysis (alpha2-antiplasmin, plasminogen, PAP, D-dimer). Children were in a hypercoagulable state after four weeks of dexamethasone due to upregulation of coagulation parameters. Upregulation was highest in the two youngest age groups. During L-Asparaginase treatment the 11- to 16-year-olds showed lower values in procoagulant and, even more, in anticoagulant factor levels compared to the younger children. Activation markers of thrombin generation and fibrinolysis did not change over time during the study period. Decreased synthesis of alpha2-antiplasmin and plasminogen during L-Asparaginase treatment resulted in less potential of clot lysis by plasmin in children older than 11 years of age. In conclusion, a more severe decline of anticoagulant and fibrinolytic parameters in children between 11 and 16 years of age underline that these children are at higher risk of thrombosis during ALL induction treatment.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18690355

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  11 in total

1.  The eukaryotic initiation factor 2 kinase GCN2 protects against hepatotoxicity during asparaginase treatment.

Authors:  Gabriel J Wilson; Piyawan Bunpo; Judy K Cundiff; Ronald C Wek; Tracy G Anthony
Journal:  Am J Physiol Endocrinol Metab       Date:  2013-09-03       Impact factor: 4.310

2.  Thromboembolism in acute lymphoblastic leukemia: results of NOPHO ALL2008 protocol treatment in patients aged 1 to 45 years.

Authors:  Cecilie Utke Rank; Nina Toft; Ruta Tuckuviene; Kathrine Grell; Ove Juul Nielsen; Thomas Leth Frandsen; Hanne Vibeke Hansen Marquart; Birgitte Klug Albertsen; Ulf Tedgård; Helene Hallböök; Ellen Ruud; Kirsten Brunsvig Jarvis; Petter Quist-Paulsen; Pasi Huttunen; Ulla Wartiovaara-Kautto; Ólafur Gísli Jónsson; Sonata Saulyte Trakymiene; Laimonas Griškevičius; Kadri Saks; Mari Punab; Kjeld Schmiegelow
Journal:  Blood       Date:  2018-04-16       Impact factor: 22.113

Review 3.  Management of Concurrent Pregnancy and Acute Lymphoblastic Malignancy in Teenaged Patients: Two Illustrative Cases and Review of the Literature.

Authors:  Alia Zaidi; Liza-Marie Johnson; Christopher L Church; Wendy C Gomez-Garcia; Marcela I Popescu; Judith F Margolin; Raul C Ribeiro
Journal:  J Adolesc Young Adult Oncol       Date:  2014-12-01       Impact factor: 2.223

4.  The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols.

Authors:  Rachael F Grace; Suzanne E Dahlberg; Donna Neuberg; Stephen E Sallan; Jean M Connors; Ellis J Neufeld; Daniel J Deangelo; Lewis B Silverman
Journal:  Br J Haematol       Date:  2011-01-07       Impact factor: 6.998

5.  Endothelial dysfunction and thromboembolism in children, adolescents, and young adults with acute lymphoblastic leukemia.

Authors:  Liv Andrés-Jensen; Kathrine Grell; Cecilie Utke Rank; Birgitte Klug Albertsen; Ruta Tuckuviene; Rikke Linnemann Nielsen; Line Stensig Lynggaard; Kirsten Brunsvig Jarvis; Petter Quist-Paulsen; Sonata Saulyte Trakymiene; Rūta Semaškevičienė; Kadri Saks; Olafur Gisli Jonsson; Thomas Leth Frandsen; Pär Ingemar Johansson; Kjeld Schmiegelow
Journal:  Leukemia       Date:  2021-08-13       Impact factor: 11.528

6.  Asparaginase Potentiates Glucocorticoid-Induced Osteonecrosis in a Mouse Model.

Authors:  Chengcheng Liu; Laura J Janke; Jitesh D Kawedia; Laura B Ramsey; Xiangjun Cai; Leonard A Mattano; Kelli L Boyd; Amy J Funk; Mary V Relling
Journal:  PLoS One       Date:  2016-03-11       Impact factor: 3.240

7.  Venous thromboembolism in a large cohort of children with acute lymphoblastic leukemia: Risk factors and effect on prognosis.

Authors:  Irene L M Klaassen; Mandy N Lauw; Marta Fiocco; Inge M van der Sluis; Rob Pieters; Saskia Middeldorp; Marianne D van de Wetering; Hester A de Groot-Kruseman; C Heleen van Ommen
Journal:  Res Pract Thromb Haemost       Date:  2019-02-27

8.  THROMBOTECT - a randomized study comparing low molecular weight heparin, antithrombin and unfractionated heparin for thromboprophylaxis during induction therapy of acute lymphoblastic leukemia in children and adolescents.

Authors:  Jeanette Greiner; Martin Schrappe; Alexander Claviez; Martin Zimmermann; Charlotte Niemeyer; Reinhard Kolb; Wolfgang Eberl; Frank Berthold; Eva Bergsträsser; Astrid Gnekow; Elisabeth Lassay; Peter Vorwerk; Melchior Lauten; Axel Sauerbrey; Johannes Rischewski; Andreas Beilken; Günter Henze; Wolfgang Korte; Anja Möricke
Journal:  Haematologica       Date:  2018-09-27       Impact factor: 9.941

9.  Knockdown of asparagine synthetase A renders Trypanosoma brucei auxotrophic to asparagine.

Authors:  Inês Loureiro; Joana Faria; Christine Clayton; Sandra Macedo Ribeiro; Nilanjan Roy; Nuno Santarém; Joana Tavares; Anabela Cordeiro-da-Silva
Journal:  PLoS Negl Trop Dis       Date:  2013-12-05

10.  Cell-based laboratory evaluation of coagulation activation by antineoplastic drugs for the treatment of lymphoid tumors.

Authors:  Misae Tsunaka; Reina Arai; Ayaka Ohashi; Takatoshi Koyama
Journal:  SAGE Open Med       Date:  2016-07-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.